The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. - Wikidata - wikimedia - TriplyDB

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

http://www.wikidata.org/entity/Q33613105

about

Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model Cooperative epigenetic modulation by cancer amplicon genes Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Targeting the tumor microenvironment: JAK-STAT3 signaling Targeting JAK2 in the therapy of myeloproliferative neoplasms The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?Targeting SH2 domains in breast cancer The therapeutic value of targeting inflammation in gastrointestinal cancers Berberine Inhibits Invasion and Metastasis of Colorectal Cancer Cells via COX-2/PGE2 Mediated JAK2/STAT3 Signaling Pathway AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines Immunity, Inflammation, and Cancer STAT3 negatively regulates thyroid tumorigenesis STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling Role of STAT3 in cancer metastasis and translational advances.Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR.Stat3 regulates centrosome clustering in cancer cells via Stathmin/PLK1.A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.Therapeutic modulators of STAT signalling for human diseases Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma Vaccine prevention of cancer: can endogenous antigens be targeted?Proinflammatory Cytokines IL-6 and TNF-α Increased Telomerase Activity through NF-κB/STAT1/STAT3 Activation, and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells.JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling Generation and characterization of a JAK2V617F-containing erythroleukemia cell line.Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation.A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.STAT3 activation in monocytes accelerates liver cancer progression.

P2860

Q21090788-7847CFC9-1400-4CB8-A202-A558424EB1F2 Q24608701-A4FF9411-06AA-4A69-A79E-C7E06FC05EC8 Q24617270-EAD0B712-7361-48CE-931F-3FA2E2FECA19 Q26751224-2E17512D-D54C-45DA-AF40-12CF96F2C483 Q26825658-484A6686-9C1A-464C-B266-2D3F560B9321 Q26860796-342DC6FB-139E-42BB-97B3-B52CA0F0D631 Q26861758-C38144E5-09FF-40BA-8053-F3FEF7CF5A56 Q27002547-6A9A6E90-C0C0-47C1-9326-E80F4CD8BD0E Q27012572-0C6587F7-01C6-4B6E-AC5A-8DC9E2A718A0 Q27014674-FE3464A1-507E-44EB-B293-09D5A021B20D Q27024203-4E41EAE1-2C1E-489D-9836-53EFB72DAF56 Q27309703-C4F4FA33-AA5F-4672-BA9B-04D717737433 Q27851932-442167C9-2630-4B03-B643-E23D7921F7D0 Q27861048-5D4E96C0-E9B1-4344-9A35-078B893D650E Q28505424-E16A0081-4CEB-4568-B1F8-501D8A6E2642 Q28538302-1BCA9222-5B84-4749-AA60-39C281FD2BB7 Q28552654-E26009E9-2FB1-4DDB-B429-792DC5EC04E6 Q28741023-1990ABDF-DC6E-4D88-BFFF-1ABD2E9876E3 Q31142794-CEBDC46A-094E-4014-A567-1AEE560533E3 Q33397219-0ACC5181-A58F-4074-81AF-588DC1679611 Q33402522-4B147009-FC9B-471F-BE86-B90BEF3621F0 Q33556931-CF737728-B9E8-4C12-AF64-B71F34D3EA32 Q33572246-D2CE1523-1570-4625-98E5-BBC4360873B8 Q33654342-2D27300F-8D4C-4046-B914-B6B9A44B2BD5 Q33661939-55AFCE3B-FD59-4D47-BFF5-666A8758DB89 Q33684732-AAB0CC0F-A932-492C-B609-7768120F8BDB Q33685977-C4A8F76C-D61A-4F69-BEDD-702856992090 Q33731768-DAB106F7-8024-443A-801E-31A777083173 Q33737707-7A234A7B-2396-4A5F-B621-8DA573332146 Q33761711-F99AA919-7441-42A4-BF85-42795DC6B5BA Q33783609-26332BEF-D9CA-49AC-9DAD-F363D6B2983B Q33813680-7BB12EFD-BCC3-44CD-B6FA-EF7D69357CB5 Q33854898-8E775E5A-1F53-464A-92DE-5C957D9C0270 Q33921220-F0DDBB60-5F4D-40E3-A3F4-292636E2B0EC Q33921803-7924D00C-90B0-4983-A49A-70C12386207C Q33959754-C2C35046-0333-4DEC-9844-5D978F0E2C8D Q33978723-9B5672CB-A3E0-474F-9333-A27AF544DED5 Q33994726-A48A36F9-FD10-42B3-879C-BB16A867F44C Q34021753-A5B38EEA-D255-4B1F-843A-F8615AA70DD5 Q34089708-E77C9F25-33F7-4225-A6FD-2517AA9322FE

P2860

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

http://www.wikidata.org/entity/Q33613105

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

The JAK2 inhibitor AZD1480 pot ...... d oncogenesis in solid tumors.

@ast

The JAK2 inhibitor AZD1480 pot ...... d oncogenesis in solid tumors.

@en

type

label

The JAK2 inhibitor AZD1480 pot ...... d oncogenesis in solid tumors.

@ast

The JAK2 inhibitor AZD1480 pot ...... d oncogenesis in solid tumors.

@en

prefLabel

The JAK2 inhibitor AZD1480 pot ...... d oncogenesis in solid tumors.

@ast

The JAK2 inhibitor AZD1480 pot ...... d oncogenesis in solid tumors.

@en

P1433

Q33613105-765BC0F5-3177-4FAF-A777-547F7D95F1A5

P1476

Q33613105-31C57A81-C19D-4A68-87E6-630C4A4D525B

P2093

Q33613105-06CEF4E4-79C6-4CA6-9FA9-4E06EFDA96AE

Q33613105-16EAFF63-7BE1-44C7-B6F2-CD9136C9D914

Q33613105-19402526-F34D-4771-89DD-C8C37A8EBEC8

Q33613105-1F8544B8-AFFB-4574-87F4-D164F4A6B694

Q33613105-1FAE411B-2F3F-429E-8434-93634FD04FA5

Q33613105-214EA3BA-984B-470A-B6A0-1266354B61A6

Q33613105-2412BF2A-645E-400E-85C9-4736AA0E66BF

Q33613105-4B798B7D-68CB-42AF-87F4-029ADABC61B7

Q33613105-4E534DC0-7502-4272-ADE4-46FC0CB8394E

Q33613105-50354F02-20C1-423B-B563-9E1E4A6CD075

P2860

Q33613105-01A15F5A-0B71-4BFD-BD41-5E7382FDF4A7

Q33613105-0D91EBA0-DFBE-4F14-9B43-7ABF763A7C71

Q33613105-0DB80A04-1EC9-4EE5-A80C-21C9A8F50B04

Q33613105-0E7026F3-1A75-4600-A108-FAD339E4B460

Q33613105-15FF2AF4-2419-4F3B-9B15-AA971F808C95

Q33613105-166A82D7-6C5B-4AEE-B028-6293A4B4AA9C

Q33613105-1D851D40-4014-4034-B4D6-D1B53A3DAAE2

Q33613105-24A42B04-3867-4DB6-BCC8-4B4DEC6BF401

Q33613105-2CD422FE-18E9-4D18-9D7F-B260967E4A63

Q33613105-3BB1B2D9-DDC4-4E5D-AC4A-630F4BA6B5BB

P304

Q33613105-4E7EDD30-E91C-4DAF-B11F-6A4B2F7DA9E0

P31

Q33613105-3B07EF98-01D8-4BFA-908E-3EC2016AA9B0

P356

Q33613105-1225243C-6782-419B-9194-C407D20ED5C2

P433

Q33613105-B529FCF4-0DAE-483F-B63C-8A3E62326268

P478

Q33613105-26081435-DB7B-462C-91AC-1B187C83AF8E

P577

Q33613105-78AAD5E5-4573-4C78-95CA-A9ED8DFE05A0

P5875

Q33613105-67B32ABA-29A4-4A81-AC67-DBF81CD46F42

P698

Q33613105-F72E8E29-8C15-49B4-BDA4-1C6325C255D4

P932

Q33613105-82980F66-7B90-4FE0-9340-489F60E67513

P356

J.CCR.2009.10.015

P1433

P1476

The JAK2 inhibitor AZD1480 pot ...... d oncogenesis in solid tumors.

@en

P2093

Adam Sheehy

http://www.w3.org/2001/XMLSchema#string

Andreas Herrmann

http://www.w3.org/2001/XMLSchema#string

Anne Schroeder

http://www.w3.org/2001/XMLSchema#string

Brian Armstrong

http://www.w3.org/2001/XMLSchema#string

Claudia M Kowolik

http://www.w3.org/2001/XMLSchema#string

David Proia

http://www.w3.org/2001/XMLSchema#string

Deborah Morosini

http://www.w3.org/2001/XMLSchema#string

Dennis Huszar

http://www.w3.org/2001/XMLSchema#string

Geraldine Bebernitz

http://www.w3.org/2001/XMLSchema#string

Hong Xin

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

Induction of epithelial tubules by growth factor HGF depends on the STAT pathway

STATs and gene regulation

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

The STATs of cancer--new molecular targets come of age

Stat3 as an oncogene

STATs in oncogenesis

Transcriptional responses to polypeptide ligands: the JAK-STAT pathway

P304

487-497

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2009.10.015

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40449647

http://www.w3.org/2001/XMLSchema#string

P698

19962667

http://www.w3.org/2001/XMLSchema#string

P932

2812011

http://www.w3.org/2001/XMLSchema#string